Home / Transcripts / MetLife, Inc. (MET) · February 5, 2026

MetLife, Inc. (MET) Earnings Call Transcript & Summary

February 5, 2026

New York Stock Exchange US Financials Insurance earnings 58 min

What were the key takeaways from MetLife, Inc.'s February 5, 2026 earnings call?

In the fourth quarter of 2025, MetLife, Inc. reported strong adjusted earnings of $1.6 billion or $2.49 per share, marking a 24% increase from the previous year. For the full year, adjusted earnings reached $6 billion or $8.89 per share, up approximately 10%. The company highlighted robust growth in its Group Benefits and Retirement segments, with adjusted premiums and fees rising 8% to $12.8 billion. Management maintained its guidance for double-digit adjusted EPS growth in 2026, signaling confidence in continued momentum across its business segments.

What topics did MetLife, Inc. cover?

What were MetLife, Inc.'s February 5, 2026 results?

MetLife's strong earnings growth and strategic initiatives position it well for continued success in 2026. The company is on track to meet its long-term financial commitments, but analysts will be closely monitoring the performance of the Group Benefits segment and macroeconomic factors that could impact sales. Investors should watch for developments in the integration of PineBridge and the ongoing execution of the New Frontier strategy.

Earnings Call Speaker Segments

John Hall executive
#1

Thanks so much, operator, and a good morning to all of you. We're glad you could be with us today for MetLife's call covering fourth quarter 2025 results along with our near-term outlook. Ahead of getting started, I'd like to direct your attention to the details regarding non-GAAP measures that appear on the investor relations section of MetLife.com, in our earnings release, and within our quarterly financial supplements — those materials deserve your review. Joining us on this morning's call are Michel Khalaf, our President and Chief Executive Officer, and John McCallion, our Chief Financial Officer and Head of MetLife Investment Management. Other members of senior management are also on hand to take part in the discussion. Yesterday evening, we posted an earnings call presentation covering the quarter and our near-term outlook, and you can find it on our website. John McCallion will walk through that presentation during his prepared remarks. An appendix to the deck includes outlook sensitivities, disclosures, GAAP reconciliations, and additional information that you should review as well. Once the prepared remarks conclude, we'll move to a Q&A session, and that will wrap up right at the top of the hour. One reminder: kindly keep yourself to one question plus one follow-up. With that said, I'll turn things over to Michel.

Michel A. Khalaf executive
#2

Thanks, John, and good morning to all of you. A year ago, when New Frontier was introduced, we laid out four strategic priorities placing a stronger focus on growth. Across the last 12 months, we've moved those priorities forward — expanding the business in a responsible way, putting capital to work prudently, and running the organization with speed and discipline — even as we steered through shifting conditions in the markets and the economy. As proof of our leadership position, our group benefits business, which is best-in-class, brought in roughly $600 million of additional adjusted premiums, fees, and other revenues during 2025, and higher margin voluntary PFOs climbed 10% year-over-year. Scale, technology, and discipline keep propelling this appealing business ahead. We took advantage of our distinctive retirement platform by seeding a sidecar, Chariot Re, entering the U.S. retail retirement space through flow reinsurance, and generating over $14 billion in pension risk transfer sales — the largest annual PRT figure ever for MetLife. To speed up growth in asset management, we completed the purchase of PineBridge Investments and set up a new business segment, MetLife Investment Management. At year-end, MIM's assets under management stood at $742 billion, compared with roughly $600 billion 12 months earlier. Our international markets, which are high-growth, showed their strategic value through impressive growth rates. In 2025, Asia's constant currency sales climbed 18%, with Japan delivering a solid lift, and Latin America's constant currency sales grew 12%, led by Mexico. Our business expansion has been fueled by disciplined capital deployment and management, and in that regard, 2025 marked a pivotal year for MetLife; we expect to have put roughly $4 billion toward organic new business during 2025, owing in part to PRT origination along with the Asia and LatAm sales output I just referenced. During the period, common stock repurchases returned about $2.9 billion to shareholders, while common stock dividends accounted for an additional $1.5 billion, bringing the combined figure to roughly $4.4 billion. At the same time, we financed approximately $1.2 billion in acquisitions and business investments, among them PineBridge and Mesirow, made two investments in Chariot Re, and increased our stake in PNB MetLife, our joint venture in India. Several strategic reinsurance transactions were also completed. Those consisted of two separate agreements with Chariot Re covering about $11 billion of liabilities, plus a risk transfer arrangement with Talcott covering $10 billion of liabilities. Alongside the launch of our New Frontier strategic priorities last year, we unveiled a new batch of five-year financial commitments highlighting MetLife's exceptional value proposition. Those commitments do more than push us — crucially, they keep us answerable. We pledged to deliver double-digit Adjusted EPS growth across that period, while acknowledging the journey won't always move in a straight line. Looking back at 2025, our Adjusted EPS came in up roughly 10% when you set aside notable items. We had committed to delivering an Adjusted return on equity between 15% and 17%, and for the full year, not counting notables, we landed at 16%. We also aimed to trim 100 basis points over a five-year span, bringing our Direct Expense Ratio to 11.3%. In 2025 alone, leveraging AI along with other emerging technologies, we got that direct expense ratio down to 11.7%, which puts us well ahead of where we planned to be. Then there's the point where it all comes together — free cash flow. Our commitment was to generate $25 billion over five years. In 2025, we put down $4.9 billion as an initial installment against that cumulative goal. Throughout the Next Horizon period and continuing into New Frontier, transformation has remained the one thing we can count on. Our portfolio of category-leading operations is built to perform in any climate, which means MetLife can adjust and thrive no matter what the economy throws at us. As we mark one year of New Frontier, the evidence shows our approach is correct for this moment, aimed at the proper avenues for expansion and assessed through the proper yardsticks. Now for the fourth quarter, adjusted earnings came in strong at $1.6 billion, equal to $2.49 per share. Excluding notable items, the figure was $2.58 per share, a 24% increase from $2.08 per share during the same period last year. When you set aside notable items, that stands as the best EPS quarter in MetLife's history. What drove the quarter's strong results was solid momentum in the underlying business across the majority of our segments, and we got an additional lift from variable investment income, which improved for a second quarter in a row and came to $497 million. Returns on our private equity portfolio reached 2.8% for the quarter, and our real estate and other funds also posted a slight recovery in returns. Adjusted premiums, fees, and other revenues — what we call PFOs — climbed 8%, reaching $12.8 billion, and once retained pension risk transfer deals are factored in, the increase was 29% to $18.6 billion. For the entirety of 2025, adjusted earnings, excluding notable items, came in at $6 billion, or $8.89 per share, which represents an increase of about 10%. The rise in earnings per share was fueled by greater variable investment income, growth in volume, and capital management. During the fourth quarter, our standard practice is to share near-term objectives and additional guidance components within the earnings call presentation. Given the changes we've made to our reporting segments, we've adopted a more detailed format this time around; shortly, John will provide a thorough walkthrough of what we expect in the near term, but at a broader level, it should be clear that we remain on course to fulfill the 5-year commitments tied to adjusted EPS, adjusted ROE, direct expense ratio, and free cash flow, along with other goals set forth under New Frontier. Now looking at MetLife's individual operations, Group Benefits adjusted earnings, when notable items are excluded, came to $465 million for the fourth quarter, which helped bring full-year adjusted earnings ex notables to $1.7 billion. On the mortality side, the favorable direction we've been seeing should carry into 2026. Dental is back at target profitability thanks to repricing, though disability results came in below what we had expected for the quarter. For this year, we're looking at adjusted earnings growth of 7%-9% versus last year, with PFO growth as the main driver and underwriting providing support. In Retirement and Income Solutions, adjusted earnings excluding notable items were $454 million for the quarter, up 18%, bringing the full-year figure for adjusted earnings ex notables to $1.7 billion. Across the year, RIS benefited from record origination in both PRT and U.K. longevity reinsurance. In Asia, adjusted earnings ex notables totaled $444 million for the quarter and $1.6 billion for the year. Solid year-over-year revenue gains, driven largely by newly launched offerings — particularly those tied to foreign currencies in Japan and Korea — pushed general account assets under management up 7% on a constant currency basis during 2025. Turning to Latin America, adjusted earnings came in at $227 million once notable items were excluded, which works out to a 13% rise for the quarter. The region has delivered remarkable business momentum over the last few years, supported by growth in digital platforms like Accelerator as well as expanding strategic partnerships. Given how strong the segment performed this quarter, it's easy to envision a path to $1 billion in annual adjusted earnings in the near term. Turning to EMEA, this segment keeps outperforming what we projected for it a year ago. Adjusted earnings excluding notables came in at $97 million for the quarter, roughly matching the run rate our 2026 outlook suggests. Finishing up the business highlights, in the fourth quarter we moved to a new segmentation structure, rolling out MetLife Investment Management as a business segment.

Michel A. Khalaf executive
#3

This fits with the strategic priorities of our New Frontier plan, mirrors the critical mass we've built through acquiring PineBridge, and highlights our aim to expand and further take advantage of rising conversions between life insurance and asset management. Turning to cash and capital, the fourth quarter is a great illustration of just how strong and flexible MetLife's capital position is. We retired $500 million of debt, repurchased roughly $430 million of common stock, paid about $370 million in common stock dividends, and put close to $1 billion toward acquisitions and other investments — and after all of that, we closed out the year holding $3.6 billion in cash and cash equivalents. That sits squarely inside our target liquidity buffer of $3 billion-$4 billion. One last point on capital: during January, we bought back an additional $200 million of our common stock. For 2026, we anticipate repurchases will match those of 2025. To sum up, the strategic moves we made during 2025 lay the groundwork for the years ahead under New Frontier and put MetLife in position to meet our financial commitments and deliver on our superior value proposition — responsible growth and attractive returns with less risk. We head into 2026 as a stronger company, with business momentum that's sustained and market leadership that keeps expanding. Even as the macro and market environments keep shifting, our focus stays fixed on the levers within our control and on relentless execution, so we can generate responsible growth, deploy capital with rigor, and further drive operating efficiency. MetLife's financial strength underpins our capacity to deliver for shareholders and for other stakeholders too, among them our customers, employees, and communities. During 2025, MetLife paid out approximately $50 billion in policyholder benefits and claims and invested over $90 billion in support of our liabilities. The pure scale of those figures spotlights how devoted our people are to MetLife's purpose — always with you, building a more confident future. Our team's commitment energizes me, and I look forward to what's ahead, since there's still much for us to accomplish; at this point, I'll hand things to John, who will walk through our performance and outlook in more detail.

John McCallion executive
#4

Thank you, Michel, and good morning to all of you. I'll walk through the results for our fourth quarter and will reference the earnings call presentation for the fourth quarter as I go over the financial highlights, which include our near-term outlook. If we begin on page three, during 2025 we advanced considerably toward the financial goals we set for five years. We delivered 10% growth in adjusted EPS along with an adjusted ROE of 16%, which sits inside our target range, a two-year average free cash flow ratio of 81%, which came in above target, and a direct expense ratio for the full year of 11.7%, which also exceeded our target. On the whole, a very strong first year, one that lays a solid foundation for what we call our New Frontier strategy. Net income came to roughly $800 million for the fourth quarter and $3.2 billion for the full year of 2025. Most of the gap between net income and adjusted earnings stemmed from net derivative losses, driven largely by long-term interest rates moving higher, favorable equity markets, and a stronger U.S. dollar; we rely on derivatives to hedge economic exposures, and those offsets either show up elsewhere in the financial statements or the offsetting economics appear over time; beyond that, net investment losses were mostly the product of routine trading activity within the portfolio, and credit stayed stable. During the fourth quarter we had two notable items, and together they cut adjusted earnings by $61 million, which equals $0.09 per share. Those notable items were the Mexico VAT impact that we talked about in the third quarter, plus higher asbestos litigation reserves booked in corporate and other. Turning to page 4, this slide shows a year-over-year comparison of fourth quarter adjusted earnings, excluding notable items, broken out by segment along with corporate and other. Every comment I make refers to figures that exclude notable items. Adjusted earnings increased 18%, or 17% in constant currency, reaching $1.7 billion, pushed up by higher variable investment income, robust volume growth, and favorable expense margins, and partly held back by lower recurring interest margins. In addition, we have changed our definition of adjusted earnings so that it excludes the non-cash accounting of real estate depreciation, which aligns how real estate asset value changes are treated and gives a better picture of the recurring cash flow and returns from the investment within adjusted earnings; this change lifted fourth quarter adjusted earnings by $57 million and should contribute roughly $200 million each year, with the benefit falling mostly to corporate and other. Adjusted earnings per share came in at $2.58, which is up 24%, or 23% on a constant currency basis. That growth was underpinned by disciplined capital management. Now on to the businesses: adjusted earnings in group benefits were $465 million, a rise of 12% year-over-year, mainly fueled by favorable underwriting, chiefly in life and dental, and partly offset by weaker disability. For the quarter the group life mortality ratio was 81.1%, and for the full year it was 83.1%, both under our 2025 target range of 84%-89%, which mirrors continuing improvement in working age mortality trends. The fourth quarter non-medical health interest-adjusted benefit ratio of 72.2% landed within our annual target range. Dental utilization was seasonally low and matched expectations. Disability results, though, fell short of expectations because average severity was higher and incidence was higher during the quarter, even though both remained within pricing expectations. For group benefits, adjusted PFOs in Q4 and the entire 2025 fiscal year rose 2% compared to the same period a year earlier. If you set aside the effect of about 2 percentage points tied to participating life contracts, that increase becomes 4%. RIS adjusted earnings came in at $454 million, an 18% gain versus the prior year, largely because variable investment income was higher. Investment spreads, once VII is excluded, stayed fairly steady at 99 basis points, which is 1 basis point higher than the previous quarter. RIS saw significant inflows during 2025, fueled by record sales totaling $42 billion over the year. Pension risk transfers exceeded $14 billion, while U.K. longevity deals reached $11 billion, with $7 billion of that occurring in Q4. The power of this origination platform and its expansion across 2025 highlights worldwide appetite for life and retirement solutions, along with our determination to use strategic reinsurance to boost capital flexibility in support of that trend. Asia adjusted earnings totaled $444 million, basically unchanged from a year ago, and 1% higher when measured in constant currency. Volume growth and favorable expense margins were the main factors. These gains were partly counterbalanced by weaker underwriting margins relative to the prior-year quarter, which had included positive reserve refinements that added roughly $30 million to adjusted earnings. Asia's major top-line growth measures were strong in Q4 and across all of 2025. General account assets under management at amortized costs climbed 7% in constant currency. Sales increased 18% in constant currency for both the quarter and the full year, mainly powered by Japan and Korea, the region's two biggest markets. Latin America adjusted earnings reached $227 million, rising 13% and up 4% in constant currency, thanks to volume growth throughout the region. Latin America's adjusted PFOs grew 25% and 16% in constant currency, while sales climbed 26% in constant currency on the back of strong regional growth, especially in Mexico and Brazil. EMEA adjusted earnings were $97 million, a 64% increase on both a reported and constant currency basis. The main factors were solid volume growth and favorable underwriting margins. EMEA adjusted PFOs rose 21% and 17% in constant currency. Sales gained 24% in constant currency, reflecting considerable strength across most markets, with Turkey and the U.K. leading the way. Now for MetLife Investment Management, or MIM, which is being reported as a standalone business segment for the first time. MIM posted adjusted earnings of $60 million in Q4 of 2025, compared with $16 million in Q4 of 2024. The main year-over-year factor was the shift to general account market fees as part of becoming a business segment. Going forward, we'd direct your attention to MIM's key financial metrics, which appear in our quarterly financial supplement. Beyond the statement of adjusted earnings, we supplied AUM and revenue details covering both institutional clients and the general account. On the corporate and other side — that segment now contains MetLife Holdings, the legacy run-off operation — we posted an adjusted loss of $38 million in Q4 of 2025. In the comparable quarter a year earlier, the adjusted loss came to $72 million. Favorable investment margins and expense margins drove the improvement for the most part. Those gains, though, were partly offset by life underwriting margins that came in less favorable. On page five, you can see our pre-tax variable investment income, or VII, covering each of the four quarters of full year 2025, plus full year 2024. VII reached $497 million during Q4, with private equities powering that result: they delivered an average return of 2.8%, whereas real estate and other funds averaged 1.1%. Keep in mind that PE along with real estate and other funds get reported on a one-quarter lag and are accounted for on a mark-to-market basis. Across the full year, VII totaled $1.5 billion — under our 2025 target of $1.7 billion, yet comfortably above the prior year. Real estate and other funds explain a large share of that shortfall, and PE returns — which produced a full year 2025 return of 8.2% — landed modestly below the 9% annual expected return we set; turning to page six, we break out VII post-tax by segment and corporate and other for the four quarters and full year of 2025.

John McCallion executive
#5

The bulk of our VII assets sit in Asia, RIS, and the legacy run-off operations that now fall under corporate and other — which makes sense given how long-dated those obligations are. Total VII assets came to roughly $19 billion as of December 31, 2025. Asia made up almost 45% of that, with RIS at about 30% and corporate and other at around 25%. If you'll turn to page seven, this chart compares our direct expense ratio across the fourth quarter and the full years 2024 and 2025. You can see that our efficiency mindset keeps paying off as we push our cost curve lower — the direct expense ratio dropped to 11.7% for the year, which puts us well ahead of target. That reflects gains from rolling out AI tools and other emerging technology throughout the company, where we've found chances to reengineer processes and bring in AI tools that boost how quickly and accurately we deliver, and all of that makes life better for both our customers and our employees. Now let me walk through our cash and capital position, which you'll find detailed on page eight. MetLife continues to be strongly capitalized with robust liquidity. At December 31st, cash and liquid assets held at the holding companies came to $3.6 billion, which is right in line with our target cash buffer of $3 billion -$4 billion. The PineBridge acquisition, which closed during the quarter, was the primary reason Holdco cash declined sequentially. On top of that, total cash returned to shareholders during the fourth quarter was roughly $800 million, which included about $430 million in share repurchases. We bought back an additional approximately $200 million of shares in January. Across the two-year period of 2024 and 2025, our average free cash flow ratio, excluding total notable items, came in at 81%, which is above our 65%-75% target range. When it comes to statutory capital for our U.S. companies, we expect our combined 2025 NAIC RBC ratio to land above our 360% target. Our estimated U.S. statutory adjusted capital on an NAIC basis was approximately $17.2 billion as of December 31, up 1% from the third quarter; we expect the Japan solvency margin ratio to come in around 770% as of December 31, though the final statutory filings aren't due for a few weeks. Keep in mind this will be the final stat filing in Japan using the SMR, since we'll be moving to an economic solvency ratio, or ESR. As we've said before, we expect to report an initial ESR in the range of 170%-190% for March 2026. Let's move on to our outlook, beginning with the overview on page 10. Assuming the forward currency curve holds, we expect the U.S. dollar to remain stable in 2026 compared with 2025. The forward interest rate curve points to long-term interest rates being modestly higher and the yield curve steepening, which is a positive. We're using an assumption of 5% annual return for the S&P 500. For our near-term targets, we expect to deliver double-digit adjusted EPS growth. Our projection for adjusted ROE sits between 15% and 17%. Over a two-year span, we anticipate holding our free cash flow ratio at 65%-75% of adjusted earnings, and that underpins a five-year pledge to produce more than $25 billion in free cash flow. Turning to 2026 in particular: since asset management operations typically carry elevated expense ratios, bringing PineBridge into the fold will push our direct expense ratio up by 50 basis points during 2026, and our goal for that year stands at 12.1%. That said, after the substantial strides achieved in year one under New Frontier toward delivering a 100 basis point gain across the five years, we plan to keep our 2029 target at 11.3%, even with the greater expense ratios that come with faster expansion in asset management. For variable investment income, we anticipate roughly $1.6 billion on a pre-tax basis. Our corporate and other adjusted loss should land somewhere between $500 million and $700 million after tax. The expected effective tax rate range stays at 24%-26%, and we anticipate share repurchases for 2026 will match those of 2025. At the bottom of the page, certain interest rate sensitivities versus our base case are shown, indicating a fairly limited effect on adjusted earnings in the near term. Our outlook for VII appears on page 11. We anticipate average asset balances for private equities will shrink in 2026 and across the near term, since we keep strategically shifting the portfolio toward higher-yielding fixed income securities, in keeping with the elevated interest rate backdrop. Over the near term, we assume private equity returns of 9% annually, with real estate and other funds at 7%. As a final reminder, prepayment fees on fixed maturities and mortgage loans are included in VII. Switching to our business segments on page 12, beginning with group benefits, our adjusted PFO growth target stays at 4%-7% over the near term while we keep reinforcing our market leadership. We are lowering the target range for our group life mortality ratio by 1 point, to 83%-88%, since we anticipate favorable mortality trends will persist through 2026. For group non-medical health, we are raising our interest-adjusted benefit ratio target range by 1 point, to 70%-75%. The advantages of our leave and absence capabilities and technology investments are gaining traction in the market, so this range mirrors our refreshed view of product mix over the near term. With all of these considerations factored in, we anticipate Group Benefits Adjusted Earnings ex notables will rise 7%-9% during 2026. Do bear in mind that Q1 is usually a seasonally weak quarter, with life and non-medical health results both leaning toward the upper end of the target ratio ranges. The near-term outlook for RIS is on page 13. Under New Frontier, we are deliberately using reinsurance to bolster our organic capital with third-party capital, supporting growing demand for retirement solutions. This adds further to our liability growth while letting us preserve capital discipline. Capital flexibility is really the thread running through all of this. Thanks to a broader set of tools now at our disposal, we can both back liability growth and create extra assets available for investment that MetLife Investment Management will oversee. Because of that, we've made the statistical pages within the QFS clearer, so they better capture how our rising reliance on reinsurance plays out. So earnings for the RIS segment will come from retained liability exposures after reinsurance is accounted for. To put a finer point on it, average retained liability exposures are projected to increase 3%-5% during 2026, and that growth leans toward the back half of the year. For 2026, we're looking at RIS adjusted earnings somewhere between $1.6 billion and $1.8 billion. Since the growth skews toward the latter half of 2026, Q1 adjusted earnings should come in roughly level compared with a year earlier. And lastly, total general account investment spread for 2026 is anticipated to land in a range of 100 basis points -120 basis points. Turning to Asia on page 14, near term we anticipate annual sales growth in the mid to high-single digits on a constant currency basis, along with general account AUM growth in the mid-single digits. Adjusted earnings for Asia, once notable items are excluded, should rise mid-single digits over the near term.

John McCallion executive
#6

On the Japan ESR, if we assume a 100 basis point move, either upward or downward, in the 10-year U.S. Treasury, the 30-year JGB rate, or both, our expectation is that we stay inside the 170%-190% target range. Turning to page 15 and Latin America, we anticipate adjusted PFOs will rise at a high-single-digit pace in the near term. For Latin America adjusted earnings, excluding notable items, our expectation is a 6%-8% increase in 2026, and that figure includes an impact of roughly $50 million tied to the Mexico VAT change, which should fall mostly in the first half of the year. We look for adjusted earnings to get back to high single digits growth in 2027 and 2028. Now on to EMEA, where we anticipate adjusted PFOs will keep growing at high single digits, thanks to strong momentum in the business. On adjusted earnings, EMEA's new quarterly run rate should rise to $90 million-$100 million in 2026, and after that grow mid to high single digits in 2027 and 2028. Last, at MIM, revenues should grow roughly 30% in 2026, driven in large part by the combination of PineBridge, and then rise by mid-single digits after that; for MIM adjusted earnings, we expect a figure between $240 million and $280 million in 2026, then growth of 15%-20% per year in 2027 and 2028, coming from revenue and expense synergies together with greater operating leverage. By 2028, our target is an operating margin of approximately 32%. Beyond that, MIM's Q1 adjusted earnings should come in at approximately $50 million, below the implied quarterly run rate, because of higher seasonal expenses in the first quarter. All told, MetLife turned in a strong quarter to close out another strong year. We carried out key strategic initiatives in support of New Frontier while meeting our financial commitments. Leveraging our clear momentum and solid fundamentals across our diverse set of market-leading businesses, we posted robust top-line growth, kept underwriting disciplined, and applied prudent expense management. Thanks to a strong balance sheet and dependable Free Cash Flow generation, we are well positioned to achieve responsible growth and deliver attractive returns with lower risk, creating sustainable value for both our customers and our shareholders. With that, I'll hand the call back to the operator for your questions.

Jimmy Bhullar analyst
#7

Morning, everyone. To start off, I've got something for Ramy regarding Group Benefits. Could you share your observations from this renewal cycle across the different product lines? You've clearly been raising dental rates over the last twelve months — so what exactly have you been doing on pricing across those product lines, and are you noticing competitors getting more aggressive or backing off in any Group Benefits products?

Ramy Tadros executive
#8

Appreciate that, Jimmy. Looking at our first-quarter numbers, especially around persistency and renewals, the results look quite strong to me. Persistency has gone up, dental in particular. As we've discussed before, during Q1 of 2025 we took steps on the dental side and moved fast to return to the margins we target, and I'd tell you that right now persistency is trending better and looks quite solid. We'll circle back with you on the complete Q1 figures, but at this stage we're also posting healthy sales growth throughout our book, and I'd call out disability specifically as a strong spot that's beginning to show up in our 1/1 results.

Jimmy Bhullar analyst
#9

Moving to a different subject now, for Lyndon or perhaps Michel. In Japan, some macro variables have moved quite sharply — be that currency or interest rates. What impact does that have on your operations when it comes to persistency, possibly the sales mix, and do you have any thoughts on how competitive that market is as well?

Lyndon Oliver executive
#10

Hi, Jimmy, Lyndon speaking. Yes, we've recently witnessed a certain amount of macroeconomic volatility, in both FX and rates. If you consider it, though, rates might be behind a near-term effect on sales; when there are major macroeconomic swings, we do notice an effect in the near term. What occurs in this situation is that our customers usually hold off until markets settle down, rather than going out to purchase products in foreign currency. So we get these brief fluctuations, yet largely speaking, the value we offer still holds up well with customers; and because our product portfolio is broad and our distribution here is strong, that genuinely places us — puts us — in a favorable spot to serve demand throughout such stretches, be it yen or dollar products.

Jimmy Bhullar analyst
#11

Turning to what's happening at Prudential — clearly those troubles are tied to that company and aren't connected to you folks — but could there be any effect on your operations simply from Pru and you both being an American firm, whether in sales, persistency, or recruiting?

Lyndon Oliver executive
#12

Yeah, well, thanks for raising that. Honestly, there isn't a great deal we can offer on it. That said, we know what's going on, and we feel quite good about where we stand in Japan. During Investor Day you heard us say we view it as a highly appealing market, what with the higher rate environment and all the favorable macroeconomic trends. Plenty of capital is flowing in, and competition there remains intense; even so, as I mentioned, our platform is genuinely solid, with robust multi-channel distribution and a product portfolio that's well diversified. Our sales results this year speak for themselves — they're up 17% — so we feel quite good about where we stand in Japan and about what we can achieve as we head into 2026.

Jimmy Bhullar analyst
#13

Thanks.

Tom Gallagher analyst
#14

Morning. John, to start, I have a question about the shift in GAAP earnings related to real estate accounting. That $200 million gain you mentioned — is that only a GAAP effect? Do you expect any statutory change, or was that adjustment already reflected in statutory? Also, why make this change? Were you being more cautious than others, or does it better capture what you see as the economics? Thanks.

John McCallion executive
#15

Yes, thanks. Morning, Tom. We've considered this for a while, and the re-segmentation and change, I think, gave us a chance to reconsider how we report adjusted earnings; and compared with peers, our allocation to real estate was likely larger given our expertise there, so we tend to favor this asset class. So we did a review as we considered it. Honestly, the non-cash cost accounting construct isn't really suited to showing the annual cash flows and annual returns of this product. It also doesn't line up well with book value changes, and then a sale can come in below. We aimed for this change to bring a bit more alignment to the overall economics of the asset class and to better reflect our operating cash flow.

Tom Gallagher analyst
#16

That does make sense. Hey, since MIM is the hot new topic everyone's focused on this quarter, I figured I'd ask about it. It's something people have been bringing up lately, so I'm wondering how much you're able to say. Brighthouse is clearly going to be bought by Aquarian. I understand they're one of your partners — you've got an investment management agreement with them. Can you give any sense of how big a deal it could be if that contract gets changed because of the acquisition? And is any of that reflected in your 2026 guidance, or is it more of a 2027 thing? Thanks.

John McCallion executive
#17

Yeah, let me begin by saying we're really thrilled to be wrapping up PineBridge as the year ends. The momentum has been great, coming together as a single team right from January 1. Just to give some context, MIM has traditionally operated as a single platform — we never really developed that boutique approach. So there's a natural path for these complementary businesses to join up and integrate, and we're genuinely excited for what's coming. Even in the period between signing and closing, our flows in MIM looked quite strong, and PineBridge performed very well; that speaks to why this deal makes sense and how the market has responded to it. So we're really looking forward to what lies ahead, and it gives us a larger, more complete, even broader range of solutions we can offer clients, especially insurance clients. We're able to serve insurance clients fully, not just push products, but truly concentrate on what serves them best. We meet their needs. And as you brought up, Brighthouse. Brighthouse is a terrific relationship for us. We share a long history and take pride in it. We're glad to have the chance to work with the newly combined firm they've formed, and I realize they're in the middle of a process right now, so we're available to support them. Ultimately, we have a varied client base throughout our MIM platform. We hold close to $150 billion of AUM in insurance, and it's a diversified group. And when it comes to exposure, while we're eager to maintain and expand our relationship with Brighthouse, that's what we expect. In the end, for the firm overall, this would be — in a worst-case scenario — a fairly small hit to EPS.

Tom Gallagher analyst
#18

All right, I appreciate that.

Joel Hurwitz analyst
#19

Hi there, good morning. Michel, during your prepared comments, you said that your company had entered the U.S. retail retirement sector through low reinsurance. Could you give us an update on what has been accomplished so far, along with how you see that opportunity shaping up now?

Ramy Tadros executive
#20

Hi Joel, this is Ramy speaking. I'll handle that question. To begin, I think you have to view this within the larger picture of our U.S. retirement approach, which we discussed under our New Frontier strategy, and at the most basic level, our method is to compete within retirement in segments that align with our strengths and make use of our competitive edge; we examined that, and within that process, examined a rapidly expanding U.S. retail annuity marketplace, and spotted a chance to take part in it in a manner that does harness our competitive advantages. And here, the route we selected is to engage with that market institutionally, acting as a reinsurer. And honestly, as proof of our disciplined execution, within less than 12 months, we carried out that strategy. We currently have 2 partners with flow reinsurance agreements established that began during the last 2 months. We appreciate these partnerships, and our partners appreciate the value we offer, especially regarding financial strength, investment capability, capital flexibility. So that's precisely what we intend when we state that we seek opportunities aligning with our strengths; and ultimately, this will enhance our capacity to grow liability origination, and seize the momentum we observe in the retirement market, in a manner that suits our economics and, and matches what we can contribute here.

Joel Hurwitz analyst
#21

Understood, that's clear. Now I just had a quick follow-up to what Jimmy asked regarding Japan, the macro picture, and persistency. Have you observed any pickup in surrender activity so far in Q4 and into Q1? And also, I'm wondering whether your outlook already accounts for the possibility of more surrenders, given where FX and rates stand?

Lyndon Oliver executive
#22

Yes. Hi Joel, Lyndon speaking. Right, we did observe that pattern — during the fourth quarter, surrenders ran somewhat above the level we'd seen sequentially in Q3, and the main driver was the yen weakening against the U.S. dollar; across the entirety of 2025, our surrender levels have declined compared with 2024. As for 2026, our assumption is that surrenders revert to the long-term assumption we use there, and that's incorporated into the 2026 guidance we've given.

Joel Hurwitz analyst
#23

Understood. Thanks a lot.

Suneet Kamath analyst
#24

Thank you. Morning, everyone. For my first question, I'd like to focus on the group business. A question that comes up repeatedly is this: AI is arriving, and it will eliminate some percentage of workers — X% — which will hurt companies in group benefits. Then, when I look at the guidance you've provided, it appears to show growth stacked on top of fairly solid growth achieved this year, so it doesn't seem like you're factoring in anything tied to that concern. Could you describe what you're observing, perhaps among customers, when it comes to hiring or reductions in force, so we can get a sense of how broad this issue is and where things currently stand?

Ramy Tadros executive
#25

Thanks, Suneet. This is Ramy speaking. Here's how I'd put it: in building our PFO outlook, we consider multiple elements. We have definitely built in what our book has shown regarding employment actions taken by certain clients, whether those are caused by AI or by other reasons. The outlook presumes that this pattern will carry on into 2026. So our perspective on how this picture develops is quite grounded. That said, our outlook also factors in the growth we're observing, whether from adding coverages for current employers and new sales, or from higher participation rates achieved through our enrollment work. Part of this is the very robust beginning to 1/1, which I mentioned previously, and that beginning has been robust both in persistency in sales and in sales throughout the whole book, including disability. So, taking all of these elements together, we're at ease with the outlook range. Our book's diversified character across industry, employer size, and geography all serve as helpful elements for us in this situation, should we witness more ebbs and flows regarding employment levels across economies as well as across sectors. So, all things considered, we're at ease with the outlook, and we are factoring in what we're genuinely observing in the form of employment actions in our book too.

Suneet Kamath analyst
#26

All right, that's useful. Then, for John, regarding capital, I'd like to raise the topic of Japan, since one thing we've been picking up on is that, as you know, unrealized losses over in Japan may affect the dividend formulas, so to speak, when it comes to moving capital out. So I was hoping you might speak to that and sort of how you see it unfolding in 2026. Thanks.

John McCallion executive
#27

Yes. Good morning, Suneet. Yes, as you mentioned, over in Japan and, frankly, other places too, you know, there are several considerations when it comes to dividend capacity, correct? You've got your solvency ratios. You also have to consider, sort of, the retained earnings; and that's accurate, but, you know, additional items from the balance sheet feed into that as well. So a number of things factor in there. I believe ultimately, as far as we're concerned, we aren't encountering any limitations on our dividend capacity in Japan; so nothing has really changed, and that covers, you know, the move to the ESR, and we believe we're sitting in a solid spot regarding, you know, retained earnings too.

Suneet Kamath analyst
#28

Could you give us a sense of how much of the Japan book has been ceded through reinsurance outside Japan?

John McCallion executive
#29

That figure isn't something I can pull from memory right away. Reinsurance is something we've been doing for a good while now — across roughly the past 10 years, I'd say. For that, we've mainly relied on our Bermuda operation. It does represent a share, though it's definitely not most of it.

Suneet Kamath analyst
#30

All right, thank you.

Wesley Carmichael analyst
#31

Good morning, and thanks. My first one is about group disability. It seems like experience was somewhat less favorable during the quarter, and the non-medical health loss ratio looked roughly flat compared with the prior period; we have heard comparable remarks, I believe, from other companies. I'm just curious whether you could break down what you observed in disability and whether you would anticipate that continuing into 2026.

Ramy Tadros executive
#32

Yes, this is Ramy; we did experience some strain during the quarter related to disability. You can view it as a bit more than 1 point on our non-medical health ratio. Several components are at play. First, across our long-term disability book, average severity came in somewhat higher. Social Security decisions were somewhat lower this quarter. Those generally move around from one quarter to another. On recoveries and incidence, I would say recoveries declined somewhat during the quarter, yet across the full year they were robust and exceeded expectations. Incidence rose somewhat during the quarter, but once again, across the full year, they were also mostly consistent with expectations. So if you consider how we would trend this, although this quarter has been unfavorable, it certainly does not establish a trend, and I would not take this quarter's outcomes and extrapolate them into 2026.

Wesley Carmichael analyst
#33

That's quite useful. And, Ramy, if I could stay with you for a moment — regarding mandated paid family leave and the products tied to it, I believe several states are introducing new required programs. But when I sort of scan the U.S. map for mandatory leave, there seems to be plenty of untouched territory. Texas isn't there, Florida isn't there, and many states in the middle of the country still lack these programs. So I realize these offerings might not be as lucrative as certain other group products, but do you view this as a significant chance to capture additional market share from MetLife as additional states launch?

Ramy Tadros executive
#34

Yeah, thanks for asking. Perhaps I'll take a step back, discuss disability broadly, then return to paid family leave, and really also reconnect you to the backdrop we described during our Investor Day. We called out the disability category overall as an appealing growth prospect. Numerous secular forces are fueling that expansion, among them the state-level regulations now arriving. We put money into this area, both to deliver top-tier capabilities to employers and their workers. We mentioned certain digital tools of ours too, and that value proposition is landing well in the market; and look, within that strategy, we also noted that employers are looking to accomplish more with less, and we described absence and disability as an anchor offering for us. And the evidence here is that most of our absence and disability sales actually get packaged together with our wider product suite. So that's the larger backdrop for disability and absence overall. Turning to paid family medical leave, it's been one component of that puzzle and one that has provided us with favorable tailwinds as additional states have introduced programs, such as Minnesota and others. And we discussed that picture persisting thanks to the untouched territory you just referenced; and our method here draws on all the capabilities I mentioned, while also drawing on the full breadth of our product lineup. And to offer yet another data point, when I examine our one-on-one sales for PFML, on average they arrived with four or five extra coverages packaged alongside those sales. So this is a truly textbook illustration of us spotting an opportunity, crafting a strategy, and simply executing very well on it, and we're extremely happy with the result.

Wesley Carmichael analyst
#35

Thanks.

Alex Scott analyst
#36

Hello, and thanks for having me on. My first question concerns corporate. I'm simply trying to get a handle on the 500 and 700. I realize there are several shifting components in play because of the re-segmentation. So, is there — I suppose what I'm really asking is whether any portion of that figure relates specifically to 2026? When I looked back at holdings and corporate, and considered what combining with MIM would involve, it simply struck me as somewhat larger than I had anticipated.

John McCallion executive
#37

Hey, good morning, Alex. What you're saying is you had assumed a higher, you would-

Alex Scott analyst
#38

Actually, my expectation wasn't for a figure quite that large, or I wouldn't have—

John McCallion executive
#39

A loss.

Alex Scott analyst
#40

I'm guessing we should anticipate a similarly large loss there.

John McCallion executive
#41

Alright.

Alex Scott analyst
#42

I just wanted to understand-

John McCallion executive
#43

Yeah.

Alex Scott analyst
#44

If there was something that leaned more toward a one-time nature for 26 within those figures. Sorry.

John McCallion executive
#45

Yeah. I mean, perhaps I'll, I'll turn to Q4 to maybe help you arrive there, right? So, on an ex-notable basis, the loss we posted was 38; and you need to factor in whether there were some, I'd say, non-recurring items in taxes, expenses; we had some reserve releases, and we had some excess quarterly NII during that quarter in C&O. That probably brings you up to a run rate of around 100; and then as you convert that into the following year, you need to factor in, and I think this matters, so I appreciate the question. You know, we completed some reinsurance transactions in the fourth quarter; so the Talcott Resolution transaction we announced, you know, that's roughly $100 million of lost earnings, and we did the Chariot Re one. So I think close to 30 of additional lower earnings from MLH, which is now in corporate and other. And then the other thing you need to factor in just for seasonality is, remember, every first and third quarter, we have about $15 million more of cost for preferred dividends. So that should assist you with your quarterly modeling, but that's, that, that's a little bit of, of what you're missing.

Alex Scott analyst
#46

Understood, that's really useful. The next item I have for you concerns artificial intelligence, and I believe you already mentioned something about how employment sensitivity plays into it and the group; but are there additional opportunities or risks you would call out? And could you also speak about exposure to software and similar areas within your investment portfolio itself? This is simply a subject that we're starting to receive far more questions about, and it's quite theoretical, difficult to respond to, but I'd be curious to hear your perspective.

John McCallion executive
#47

Hello, Alex. Perhaps I'll begin. I mean, look, I think, you know, something we take great pride in, and not only within the investment portfolio, but throughout our entire firm, is — and we bring this up rather often, quite a bit actually, at Investor Day — is diversification; and be it diversification on a geographic basis, we also have diversification when it comes to the sorts of businesses we hold. So we possess, you know, healthy, balance sheet businesses, and beyond that we have very healthy, capital light businesses spanning the globe. Beyond that, we have varying risk profiles. And then when you move to the investment portfolio, I think it's fair to state, and we've observed other figures from internal analyses that more or less confirm it, we're likely the most diversified, throughout the industry when it comes to our approach; we can achieve that since we have a fully scaled asset global asset manager, where. You know, because some folks, if you claim diversified, you'd ask, "Well, how do you remain close?" We can remain close to each credit that we underwrite and monitor thanks to our scale; so we can accomplish this because of our scale and our competitive advantages. And, you know, regarding the software point that you brought up, ultimately, you know, there are a variety of different cycles out there. This is probably in areas where I think within the industry, we're probably not all that exposed, simply given our approach to kind of investment grade-oriented investing. We've witnessed it. I'm not so certain it, you know, I, we really, you know, weigh in too much here since we don't believe it's that significant an exposure to the industry or to us.

Alex Scott analyst
#48

Understood. All right, thanks.

John Hall executive
#49

I appreciate all of you being here with us today — enjoy the rest of your day.

Operator operator
#50

This concludes today's conference call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete MetLife, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to MetLife, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.